Baer Investment Advisory LLC Buys New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Baer Investment Advisory LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,536 shares of the medical research company's stock, valued at approximately $799,000. Thermo Fisher Scientific accounts for about 1.7% of Baer Investment Advisory LLC's holdings, making the stock its 18th biggest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wormser Freres Gestion increased its holdings in shares of Thermo Fisher Scientific by 1.5% in the 4th quarter. Wormser Freres Gestion now owns 14,953 shares of the medical research company's stock valued at $7,841,000 after purchasing an additional 222 shares in the last quarter. Warm Springs Advisors Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $2,051,000. North Star Asset Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 2.9% during the 4th quarter. North Star Asset Management Inc. now owns 55,625 shares of the medical research company's stock worth $28,938,000 after acquiring an additional 1,581 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $4,930,000. Finally, University of Texas Texas AM Investment Management Co. raised its holdings in Thermo Fisher Scientific by 339.7% during the fourth quarter. University of Texas Texas AM Investment Management Co. now owns 1,662 shares of the medical research company's stock worth $865,000 after purchasing an additional 1,284 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock valued at $7,305,942 in the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 2.4%

Thermo Fisher Scientific stock traded up $9.59 during midday trading on Tuesday, hitting $403.25. 2,705,443 shares of the stock were exchanged, compared to its average volume of 1,872,755. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a 50 day moving average price of $440.05 and a two-hundred day moving average price of $503.39. The firm has a market cap of $152.22 billion, a P/E ratio of 24.40, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the firm posted $5.11 earnings per share. The company's revenue was up .2% compared to the same quarter last year. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Raymond James reissued an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Scotiabank decreased their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Finally, Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.